Actuate Therapeutics Trial Shows Improved Survival Rates

Actuate Therapeutics has published clinical trial results in Nature Medicine demonstrating significantly improved survival rates with Elraglusib combined with chemotherapy for metastatic pancreatic cancer. The study indicated a doubling of the survival rate compared to the control group, with a notable increase in median overall survival. These findings represent a promising advancement in the treatment of advanced pancreatic cancer, offering new hope for patients. The publication highlights the potential efficacy of Elraglusib as a therapeutic option in oncology.